A single-blind controlled polysomnographic study was conducted in eight healthy young male subjects to assess the effect of a cholinomimetic drug, choline alfoscerate (α-GPC), on sleep. The aim of the study was to determine whether short-term treatment with 400 mg of α-GPC TID modified sleep and, in particular, rapid-eye-movement (REM) sleep parameters. Neither sleep-induction, sleep maintenance nor sleep stage percentages were affected by α-GPC. REM sleep latency was not modified, while REM density was slightly increased. The failure to modify the architecture of sleep is noteworthy in view of the potential use of this compound for aged subjects.
|Number of pages||6|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1991|
ASJC Scopus subject areas